• Explore /
  • Poster
  • / Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.

Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.

Abstract Poster

Authors

null

Anna Rachel Minchom

Drug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom

Anna Rachel Minchom , Matthew G Krebs , Byoung Chul Cho , Se-Hoon Lee , Natasha B. Leighl , Bert O'Neil , Joshua K. Sabari , Rachel Kudgus-Lokken , Ali Alhadab , Nahor Haddish-Berhane , Donna Zemlickis , Anna Mitselos , Eileen Berkay , Joshua Michael Bauml , Roland E. Knoblauch , Peter Hellemans , Melissa Lynne Johnson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04606381

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9126)

DOI

10.1200/JCO.2023.41.16_suppl.9126

Abstract #

9126

Poster Bd #

114

Abstract Disclosures

Similar Posters

First Author: Matthew Krebs

First Author: Johanna C. Bendell

First Author: Scott Joseph Antonia

First Author: Helena Alexandra Yu